PersonGen has a mature CAR structure function screening and validation platform, specifically designed to evaluate and optimize the functionality of chimeric antigen receptor (CAR) modified T cell therapies. The core objective of this platform is to ensure the safety and efficacy of CAR-T cell therapies in clinical applications.

Through in vitro experiments and animal models, this platform systematically assesses critical functions of CAR-T cells, including specific recognition, proliferation, cytotoxicity, and safety. The process involves multiple steps such as designing CAR structures with different key components, gene transduction, functional testing, and data analysis.

This platform plays a significant role in improving CAR design, enhancing therapeutic outcomes, and reducing side effects. It is a key tool for advancing the research and clinical translation of CAR-T cell therapies.